Thursday, May 4, 2023
CONTINENTAL BREAKFAST
EXHIBITS / INDUSTRY-SPONSORED SYMPOSIA
8:00 - 9:00  
Introduction
9:00 - 9:30

Introduction to the Programme

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada


Remembering David Livingston, MD (1941-2021)

Introduction:

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada


Speaker:

Judy Garber, MD, MPH, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

SESSION 7:
New developments in HBOC management
9:30 - 11:00

CHAIR: Tuya Pal, MD, Vanderbilt – Ingram Cancer Center, Nashville, TN, USA

9:30 - 9:50

Lecture
Treatment (and prevention) of BRCA1/2-related breast cancer – Platinums, PARPs and beyond

Judy Garber, MD, MPH, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

9:50 - 10:10

Lecture
Is cure of hereditary ovarian cancer an achievable goal?

Jonathan Ledermann, MD, University College London, London, UK

10:10 - 10:20

Proffered paper 1 (S7-PP1)

10:20 - 10:30

Proffered paper 2 (S7-PP2)

10:30 - 10:40

Proffered paper 3 (S7-PP3)

10:40 - 11:00

Question and discussion period (all speakers)

BREAK & VISIT EXHIBITS
11:00 - 11:30  
Thursday
Special Interest Groups (SIGs)
11:30 - 13:00

Moderated 90-minute interactive discussions with the aim of fostering bilateral knowledge transfer. Choice of one of the following 3 SIGs.

SIG 4:

The Emotional Pedigree: addressing the heart of complex psychosocial issues in genetic counseling sessions with HBOC patients

Using an all-new series of cases, we will contrast the abstract symbols of the pedigree with the emotionally fraught situations they represent, in order to identify psychosocial challenges that affect patient decision-making and ability to absorb risk information. We will practice applying psychosocial techniques that can be incorporated into genetic counseling sessions.

  • Karen Hurley, PhD, Cleveland Clinic, Cleveland, OH, USA

SIG 5:

Exploring cut-offs: When is the risk high enough to consider salpingo-oophorectomy?

In this session, the three presenters will discuss genetic predisposition to ovarian cancer and associated risks, prediction of personalised ovarian cancer risk, the health economics supporting different thresholds for salpingo-oophorectomy and the balance of risk versus side effects of an early menopause. Attendees will participate in the discussion via interactive polls and will be encouraged to send in questions relating to these topics in advance for discussion at the SIG.

  • Helen Hanson, MBBS, MD(Res), St George's Hospital, London, UK (session lead)

  • Lesa Dawson, MD, FRCSC, University of British Columbia, Vancouver, BC, Canada

  • Ranjit Manchanda, MD, MRCOG, PhD, Wolfson Institute of Population Health, Queen Mary University of London, London, UK

SIG 6:

CanRisk Workshop – Multifactorial breast and ovarian cancer risk prediction

This will be an interactive session for health professionals who are not familiar with the Canrisk tool (www.canrisk.org) for predicting multifactorial breast and ovarian cancer risks. There will be a live demonstration of the tool and a discussion of the most frequently asked questions by users. Attendees are encouraged to register as CanRisk users in advance of the SIG and will carry out risk predictions (participants will need to bring a laptop).

  • Antonis Antoniou, PhD, University of Cambridge, Cambridge, UK (session lead)

  • Marc Tischkowitz, MD, PhD, University of Cambridge, Cambridge, UK

LUNCH BREAK & VISIT EXHIBITS
INDUSTRY-SPONSORED SYMPOSIA
13:00 - 14:30  
SESSION 8:
Polygenic risk scores in practice
14:30 - 16:00

CHAIR: Jacques Simard, PhD, FRSC, FCAHS, Centre de recherche du CHU de Québec - Université Laval, Québec, QC, Canada

14:30 - 14:50

Lecture
Polygenic risk scores and moderate risk genes

Paul James, MD, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

14:50 - 15:10

Lecture
Will polygenic risk scores for cancer ever be clinically useful?

Clare Turnbull, MD, PhD, MFPH, Institute of Cancer Research, London, UK

15:10 - 15:20

Proffered paper 1 (S8-PP1)

15:20 - 15:30

Proffered paper 2 (S8-PP2)

15:30 - 15:40

Proffered paper 3 (S8-PP3)

15:40 - 16:00

Question and discussion period (all speakers)

POSTER SESSION 2 (with break)
16:00 - 17:30